

Researcher Spotlight

Developing Practical Solutions for Global Health Challenges


**Dr. Roch
Christian
Johnson**

Dr. Roch Christian Johnson at **Universite d'Abomey-Calavi** in Benin is leading a CWR-funded Phase II pilot trial to evaluate whether the addition of beta-lactam antibiotics, amoxicillin/clavulanate approved for a variety of bacterial infections, to the standard Buruli ulcer regimen can safely shorten treatment duration and improve healing rates. If successful, this approach could reduce treatment burden for patients and health systems alike.

Dr. Johnson's work spans clinical trials, epidemiology and global health advocacy, with a commitment to evidence-driven solutions accessible in resource-limited settings. He has presented and published on topics ranging from antimicrobial therapy optimization to tropical disease management and was named a Knight of the National Order of Benin, recognizing his contributions to public health and service.

Driven by a commitment to patient well-being, Dr. Johnson has spent his career expanding access to effective, practical treatments for neglected diseases. His leadership, scientific rigor and compassion continue to shape the future of infectious disease care in West Africa and beyond.

Profile



Dr. Johnson received his PhD at the Universite d'Abomey-Calavi in Benin where he currently serves as a Professor in Environment and Public Health. He is also the Medical Director at Fondation Raoul Follereau.

CWR Funding

In this trial, Dr. Johnson and his team are studying the efficacy of adding beta-lactam antibiotics to standard of care in Buruli ulcer patients. Dr. Johnson and this trial represent three Cures Within Reach communities:

- LMICs
- Health Equity
- Pediatric



Cures Within Reach is testing already approved treatments for unsolved diseases:
driving more treatments to more patients more quickly

www.cureswithinreach.org 847.745.1252 info@cureswithinreach.org

Cures Within Reach is a 501(c)3 tax-exempt organization